T2 Biosystems Inc. (NASDAQ:TTOO)’s share price rose 5.1% during mid-day trading on Wednesday . The stock traded as high as $5.54 and last traded at $5.53, with a volume of 82,607 shares. The stock had previously closed at $5.26.

Several equities research analysts have weighed in on the company. WBB Securities upgraded T2 Biosystems from a “buy” rating to a “strong-buy” rating and upped their price target for the stock from $11.00 to $12.00 in a report on Wednesday, July 20th. BTIG Research downgraded T2 Biosystems from a “buy” rating to a “sell” rating and cut their price target for the stock from $12.00 to $4.00 in a report on Friday, July 8th. Cantor Fitzgerald restated a “buy” rating and set a $15.00 price target on shares of T2 Biosystems in a report on Tuesday, June 21st. Zacks Investment Research upgraded T2 Biosystems from a “hold” rating to a “buy” rating and set a $8.75 price target on the stock in a report on Tuesday, July 5th. Finally, Leerink Swann restated an “outperform” rating and set a $11.00 price target on shares of T2 Biosystems in a report on Monday, June 20th. Two analysts have rated the stock with a sell rating, four have issued a hold rating, three have given a buy rating and one has given a strong buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus price target of $11.03.

The company’s 50-day moving average price is $7.29 and its 200-day moving average price is $8.50. The firm’s market cap is $139.88 million.

T2 Biosystems (NASDAQ:TTOO) last issued its earnings results on Monday, May 2nd. The company reported ($0.55) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.54) by $0.01. During the same period in the previous year, the company earned ($0.53) EPS. The company earned $1.10 million during the quarter. The firm’s revenue was up 485.1% compared to the same quarter last year. Analysts forecast that T2 Biosystems Inc. will post ($2.17) earnings per share for the current year.

In related news, SVP Rahul Dhanda sold 3,589 shares of T2 Biosystems stock in a transaction on Thursday, June 30th. The stock was sold at an average price of $8.16, for a total value of $29,286.24. Following the transaction, the senior vice president now owns 3,589 shares in the company, valued at $29,286.24. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

An institutional investor recently raised its position in T2 Biosystems stock. Aisling Capital LLC boosted its position in shares of T2 Biosystems Inc. (NASDAQ:TTOO) by 12.2% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 2,830,992 shares of the company’s stock after buying an additional 307,692 shares during the period. T2 Biosystems accounts for about 5.3% of Aisling Capital LLC’s portfolio, making the stock its 6th largest position. Aisling Capital LLC owned about 13.89% of T2 Biosystems worth $30,971,000 at the end of the most recent reporting period.

T2 Biosystems, Inc is an in vitro diagnostics company engaged in developing a technology platform offering an alternative to diagnostic methodologies. The Company’s T2 Magnetic Resonance platform (T2MR) enables detection of pathogens, biomarkers and other abnormalities in a range of unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum and urine, and can detect cellular targets at limits of detection as one colony forming unit per milliliter (CFU/mL).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.